$233 Million is the total value of Prosight Management, LP's 52 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 37.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $14,303,000 | -18.8% | 227,212 | -45.9% | 6.14% | -25.5% |
| KURA | Sell | KURA ONCOLOGY INC | $11,166,000 | -22.6% | 685,000 | -52.8% | 4.79% | -28.9% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $10,102,000 | -19.6% | 90,000 | -35.7% | 4.34% | -26.2% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $8,176,000 | -23.0% | 68,500 | -34.8% | 3.51% | -29.3% |
| CUE | Sell | CUE BIOPHARMA INC | $7,605,000 | -2.9% | 310,294 | -43.8% | 3.26% | -10.9% |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $6,756,000 | +34.4% | 1,620,200 | -20.4% | 2.90% | +23.4% |
| MGTX | Sell | MEIRAGTX HLDGS PLC | $6,510,000 | -14.8% | 519,967 | -8.5% | 2.79% | -21.8% |
| QURE | Sell | UNIQURE NV | $6,449,000 | -44.7% | 143,129 | -41.7% | 2.77% | -49.2% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $5,902,000 | -64.4% | 215,000 | -61.1% | 2.53% | -67.3% |
| ALBO | Sell | ALBIREO PHARMA INC | $5,266,000 | -2.6% | 198,800 | -39.8% | 2.26% | -10.6% |
| ZGNX | Sell | ZOGENIX INC | $3,953,000 | -2.3% | 146,346 | -10.6% | 1.70% | -10.3% |
| PSNL | Sell | PERSONALIS INC | $2,448,000 | -26.9% | 188,750 | -54.5% | 1.05% | -32.8% |
| IMVT | Sell | IMMUNOVANT INC | $2,325,000 | +23.0% | 95,500 | -21.4% | 1.00% | +13.0% |
| ORGO | Sell | ORGANOGENESIS HLDGS INC | $2,057,000 | -5.3% | 535,616 | -20.3% | 0.88% | -13.0% |
| EHC | Sell | ENCOMPASS HEALTH CORP | $2,037,000 | -32.2% | 32,900 | -29.9% | 0.87% | -37.7% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $1,815,000 | -79.6% | 15,000 | -84.0% | 0.78% | -81.3% |
| EOLS | Sell | EVOLUS INC | $1,492,000 | -30.1% | 281,541 | -45.2% | 0.64% | -35.9% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $1,456,000 | -13.0% | 248,050 | -35.2% | 0.62% | -20.1% |
| AMN | Sell | AMN HEALTHCARE SVCS INC | $1,215,000 | -74.8% | 26,851 | -67.8% | 0.52% | -76.9% |
| LHCG | Sell | LHC GROUP INC | $786,000 | -83.9% | 4,509 | -87.1% | 0.34% | -85.3% |
| MITO | Sell | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $533,000 | +27.8% | 291,144 | -13.4% | 0.23% | +17.4% |
| Sell | EVOLUS INCcall | $198,000 | -35.3% | 37,400 | -49.3% | 0.08% | -40.6% | |
| MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -41,592 | -100.0% | -0.04% | – |
| THC | Exit | TENET HEALTHCARE CORP | $0 | – | -20,918 | -100.0% | -0.14% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -96,615 | -100.0% | -0.20% | – |
| NSP | Exit | INSPERITY INC | $0 | – | -12,900 | -100.0% | -0.22% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -9,223 | -100.0% | -0.39% | – |
| LGND | Exit | LIGAND PHARMACEUTICALS INC | $0 | – | -11,500 | -100.0% | -0.39% | – |
| NVST | Exit | ENVISTA HOLDINGS CORPORATION | $0 | – | -58,000 | -100.0% | -0.40% | – |
| Exit | CHANGE HEALTHCARE INCcall | $0 | – | -100,000 | -100.0% | -0.47% | – | |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -78,976 | -100.0% | -0.52% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -16,030 | -100.0% | -0.57% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -22,900 | -100.0% | -0.90% | – |
| URGN | Exit | UROGEN PHARMA LTD | $0 | – | -146,179 | -100.0% | -1.22% | – |
| TZA | Exit | DIREXION SHS ETF TRdaily sm cp bear | $0 | – | -125,000 | -100.0% | -3.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.